ecrin-mdr-crcClinical2014IPD Sharing (as of January 2021): NoSolid TumorCancer. Solid tumours in the escalation phase and colorectal cancer in the expansion groups.Colorectal CancerColorectal NeoplasmsColonSolid TumorColorectal CancerColorectal NeoplasmsCancer. Solid Tumours In The Escalation Phase And Colorectal Cancer In The Expansion Groups.ColonInterventionalhttps://newmdr.ecrin.org/Study/2195064BelgiumIrelandUnited KingdomFranceSpain11CrizotinibHistologically or cytologically confirmedDose EscalationBinimetinibPD-0325901 Binimetinib PF-02341066 (Crizotinib)RASWT/c-MET CRCPD-0325901Dose ExpansionRASMT CRCECRIN MDRCompletedfalseMEK and MET Inhibition in Colorectal CancerThis trial is designed to try two new cancer drugs together for the first time. The investigators think that they might be effective in some types of bowel cancer. The first part of the trial will see what doses of the two drugs can safely be given together. Once the investigators have identified a suitable dose combination they will look at how effective treatment is in bowel cancers where either the RAS gene is mutated, or MET is over-active. In the trial the investigators will look at samples of blood, skin and tumour to check the drugs are working in the way expected. The trial will take place in three sites in the UK and 5 sites in Europe. The trial is funded as part of the European commission’s FP7 program.2014-11-152195064NCT025100012014-000463-40ISRCTN18043777